<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812847</url>
  </required_header>
  <id_info>
    <org_study_id>InfGNMDR-Neo</org_study_id>
    <nct_id>NCT04812847</nct_id>
  </id_info>
  <brief_title>Multidrug Resistant Gram-negative Pathogen Infections in High Risk Neonates in the Northeast of Mexico</brief_title>
  <acronym>InfGNMDR-Neo</acronym>
  <official_title>Infecciones Por patógenos Gramnegativos Con Multirresistencia a Drogas en Neonatos de Alto Riesgo en el Noreste de México</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Tecnologico y de Estudios Superiores de Monterey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Tecnologico y de Estudios Superiores de Monterey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this project is to establish a prospective cohort to measure the&#xD;
      Gram-negative infection burden in neonates under special care in a regional referral&#xD;
      hospital, and to characterize all microorganisms isolates from these subjects at the&#xD;
      phenotype and genotype level, specifically in relation to the expression of multi-drug&#xD;
      resistance (MDR) associated genes (Molecular characterization of Gram-negative MDR isolates).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a mixed design approach, a cohort´s study with a nested&#xD;
      case-control analysis. Study subjects will be the gram-negative isolates at the study&#xD;
      hospital clinical laboratory. The cohort´s exposure factor will be the presence or absence of&#xD;
      a multidrug resistance gram-negative bacterial isolate.&#xD;
&#xD;
      The prospective cohort will allow the estimation of Gram-negative infection burden in the&#xD;
      study population, and the characterization of all microorganisms isolates from study subjects&#xD;
      at the phenotype and genotype level, specifically in relation to the expression of multi-drug&#xD;
      resistance (MDR) associated genes (Molecular characterization of Gram-negative MDR isolates);&#xD;
      the cohort will be formed by each neonate, from the admission to special care, the isolation&#xD;
      date and then follow-up until the resolution, being it discharge either alive, dead or by&#xD;
      transfer to another facility. Risk ratios for each of these outcomes will be calculated.&#xD;
&#xD;
      Cases-controls analysis will allow the research team to identify main risk factors present in&#xD;
      those individuals who further had or did not have a gram-negative MDR isolate, by calculation&#xD;
      of associated odds ratios for concurrent perinatal factors. Another project goal, to&#xD;
      establish correlations and measure risk factors (Odds ratios) between Gram-negative infection&#xD;
      with MDR organisms and concurrent illness and treatments offered in the special care nursery&#xD;
      (medical [antibiotics, non-steroid anti-inflammatory drugs, steroids, others], surgical, and&#xD;
      clinical procedures) in neonates under special care, will also be attained through the nested&#xD;
      cases and controls study approach.&#xD;
&#xD;
      Finally, a derivative from this project will be the establishment of the North-East Mexico&#xD;
      Regional Repository of bacterial isolates in Neonates under special care. At the first stage,&#xD;
      this repository will preserve specimens of bacteria, both Gram-negative and Gram-positive,&#xD;
      along with a specially developed anonymous database of the individuals hosting those&#xD;
      infections. In the near future, the focus of this repository may expand to fungus, parasites&#xD;
      and perhaps viral isolates preservation.&#xD;
&#xD;
      The research team has also proposed an exploratory objective, subject to budget availability,&#xD;
      and that is the characterization and comparison of the immuno-phenotype of those individuals&#xD;
      affected of Gram-negative infection with MDR resistant organisms, those with infection with&#xD;
      other organisms and those not affected by infectious complications.&#xD;
&#xD;
      All gram-negative isolates will be probed for the gene expression of 38 selected antibiotic&#xD;
      resistance loci, and 96 selected samples will be further studied by next generation&#xD;
      sequentiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Burden of Gram Negative organisms infections</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>The isolation of a gram-negative organism, from any clinical site, in neonates under clinical care in special care nursery; Incidence = New cases during the study period, Prevalence = Total cases during the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Odds ratio for the occurrence of Gram-negative MDR infections</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>To identify and measure the Odds-ratio for the occurrence of Gram-negative infection with MDR resistant organisms and all concurrent perinatal factors. This will be done through a nested case and controls study approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for the occurrence of Gram-negative MDR infections.</measure>
    <time_frame>Through study completion, an average of three months</time_frame>
    <description>To establish correlations and measure risk factors (Relative risks) between Gram-negative infection with MDR organisms and concurrent illness and treatments offered in the special care nursery (medical [antibiotics, non-steroid anti-inflammatory drugs, steroids, others], surgical, and clinical procedures) in neonates under special care. This will be attained with a cohorts study approach.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infant Newborn Disease</condition>
  <arm_group>
    <arm_group_label>Gram negative infection, MDR present</arm_group_label>
    <description>Neonates with one or more gram-negative bacterial isolates with MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gram negative infection, MDR absent</arm_group_label>
    <description>Neonates with one or more gram-negative bacterial isolates with no MDR characteristics during their clinical course in the Neonatal Intensive Care Unit of the study hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Identification of MDR characteristics</intervention_name>
    <description>Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates</description>
    <arm_group_label>Gram negative infection, MDR absent</arm_group_label>
    <arm_group_label>Gram negative infection, MDR present</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Isolated microorganism, recovered from culture plates, cryo-preserved at -80°C media until&#xD;
      analysis, and thawed and seeded onto EMB (Eosin-Methylene Blue) agar plates, will be used for&#xD;
      qrtPCR (quantitative real-time Polimerase Chain reaction)amplification of fragments of genes&#xD;
      of interest.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates, both at term and preterm, of any gestational age, under special care in the&#xD;
        Neonatology Division of a tertiary care regional perinatal center in the Northeast of&#xD;
        Mexico.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Neonates of either sex, and any gestational age, admitted to the special care nursery&#xD;
             of Hospital Regional Materno Infantil (Includes also out-born and transferred babies),&#xD;
&#xD;
          2. Treating physician´s order to draw any biological sample and send it for culture at&#xD;
             the hospital´s clinical laboratory.&#xD;
&#xD;
          3. A culture with an isolate of Gram-negative bacteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any culture negative for bacterial growth&#xD;
&#xD;
          2. Any culture with Gram-positive bacteria, or fungus growth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Javier Lara-Diaz, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cuauhtémoc Licona-Cassani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tecnológico de Monterrey, Centro de Biotecnología FEMSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marion Genevieve Brunck, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tecnológico de Monterrey, Escuela de Ingeniería y Ciencias, GIEE on Translational Omics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Javier Lara-Diaz, MD, PhD</last_name>
    <phone>+52 81 83665170</phone>
    <email>lara-diaz.vj@tec.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Rene Alcorta-García, MD, PhD</last_name>
    <phone>+52 81 11995682</phone>
    <email>mario.alcorta@tec.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Regional Materno Infantil de Alta Especialidad, Secretaría de Salud</name>
      <address>
        <city>Ciudad Guadalupe</city>
        <state>Nuevo León</state>
        <zip>67140</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario René Alcorta-García, MD, PhD</last_name>
      <phone>+52 81 11995682</phone>
      <email>mario.alcorta@tec.mx</email>
    </contact>
    <contact_backup>
      <last_name>Victor Arízaga-Ballesteros, MD, MBio</last_name>
      <phone>+52 81 14662028</phone>
      <email>arizagamd@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Nohemí Lopez-Villaseñor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleyda Monreal-Malacara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sixto F. Gutiérrez-Ramírez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleazar Puente-Vera, M Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Liliana Ruiz-Barreto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Tecnologico y de Estudios Superiores de Monterey</investigator_affiliation>
    <investigator_full_name>Victor Javier Lara-Diaz, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor-Researcher</investigator_title>
  </responsible_party>
  <keyword>Drug Resistance, Multiple, Bacterial.</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Initially, we plan to share raw data with qualified researchers and entities worldwide, but we have not yet decided a specific repository.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

